BioCentury
ARTICLE | Company News

Pipex, University of California deal

August 25, 2008 7:00 AM UTC

Pipex received an exclusive, worldwide license from the university to develop and commercialize oral dnaJP1 (formerly AT-001) for autoimmune diseases. Pipex said Androclus Therapeutics (San Diego, Ca...